Skip to content

Commit

Permalink
Adding Ari Siggaard Knoph (Novo Nordisk) as a council member.
Browse files Browse the repository at this point in the history
  • Loading branch information
Nicholas Eugenio committed Aug 21, 2023
1 parent 58449e5 commit 96ba171
Showing 1 changed file with 1 addition and 1 deletion.
2 changes: 1 addition & 1 deletion posts/2023-08-30_pharmaverse_story/pharmaverse_story.qmd
Original file line number Diff line number Diff line change
Expand Up @@ -66,7 +66,7 @@ Around the same time, Thomas Neitmann (actual Denali Therapeutics, ex-Roche) and

The idea of working together, the sense of community, and the appetite from organizations built more and more, with incentive and priority established up into the programming heads council.

Janssen had a huge effort in building R capabilities going on as well, by releasing [*tidytlg*](https://github.com/pharmaverse/tidytlg) and [*envsetup*](https://github.com/pharmaverse/envsetup)), so eventually Rimler, Stackhouse and Ross formalized [pharmaverse](https://pharmaverse.org/) and formed the council, adding in Sumesh (Janssen).
Janssen had a huge effort in building R capabilities going on as well, by releasing [*tidytlg*](https://github.com/pharmaverse/tidytlg) and [*envsetup*](https://github.com/pharmaverse/envsetup)), so eventually Rimler, Stackhouse and Ross formalized [pharmaverse](https://pharmaverse.org/) and formed the council, adding in Sumesh (Janssen) and Ari Siggaard Knoph (Novo Nordisk) later joined as the fifth council member..

At the end of their presentation ["Closing the Gap: Creating an End to End R Package Toolkit for the Clinical Reporting Pipeline."](https://www.youtube.com/watch?v=NW9qp5QOlIU), in [R/Pharma 2021](https://rinpharma.com/event/rinpharma2021/), Ben Straub's (GSK) and Eli Miller's (Atorus) welcomed the community to the [pharmaverse](https://pharmaverse.org/), a new group of packages developed by various pharmaceutical companies to support open-source clinical workflows.

Expand Down

0 comments on commit 96ba171

Please sign in to comment.